Interferon alpha prevents spontaneous apoptosis of clonal Th2 cells associated with chronic hypereosinophilia

Blood. 2000 Dec 15;96(13):4285-92.

Abstract

A recent study identified a clonal expansion of CD3(-)CD4(+)cells secreting Th2-type cytokines in 4 patients with chronic hypereosinophilia. Because interferon alpha (IFN-alpha) is used in the therapy of the idiopathic hypereosinophilic syndrome, the effects of this cytokine on the survival of clonal Th2 cells isolated from the blood of 2 patients were determined. First, these cells displayed a high rate of spontaneous apoptosis on culture in cytokine-free medium and were also sensitive to Fas-mediated apoptosis induced by soluble Fas ligand. Addition of IFN-alpha or interleukin-2 (IL-2) to culture medium resulted in significant protection against spontaneous but not Fas-induced apoptosis. Although spontaneous apoptosis of the clonal Th2 cells was clearly associated with down-regulation of both bcl-2 and bcl-x(L) levels, IFN-alpha had no significant effect on the expression of these antiapoptotic proteins, whereas addition of IL-2 resulted in higher levels of bcl-2. On the other hand, IFN-alpha decreased the numbers of cells with disrupted mitochondrial transmembrane potential both during spontaneous apoptosis and after exposure to protoporphyrin IX. Thus, IFN-alpha might promote the survival of clonal Th2 cells, an effect that could be relevant to the therapeutic approach for patients with chronic hypereosinophilia caused by clonal expansion of Th2-type cells. (Blood. 2000;96:4285-4292)

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Apoptosis / drug effects*
  • Cells, Cultured
  • Chronic Disease
  • Clone Cells / drug effects
  • Fas Ligand Protein
  • Female
  • Gene Expression Regulation
  • Genes, bcl-2
  • Humans
  • Hypereosinophilic Syndrome / drug therapy
  • Hypereosinophilic Syndrome / immunology*
  • Hypereosinophilic Syndrome / pathology
  • Immunologic Memory
  • Immunophenotyping
  • Interferon alpha-2
  • Interferon-alpha / pharmacology*
  • Interferon-alpha / therapeutic use
  • Interleukin-2 / pharmacology
  • Intracellular Membranes / drug effects
  • Membrane Glycoproteins / pharmacology
  • Mitochondria / drug effects
  • Permeability / drug effects
  • Proto-Oncogene Proteins c-bcl-2 / biosynthesis
  • Proto-Oncogene Proteins c-bcl-2 / genetics
  • Protoporphyrins / pharmacology
  • Reactive Oxygen Species
  • Recombinant Proteins / pharmacology
  • Superoxides / metabolism
  • Th2 Cells / drug effects*
  • bcl-X Protein
  • fas Receptor / physiology

Substances

  • BCL2L1 protein, human
  • FASLG protein, human
  • Fas Ligand Protein
  • Interferon alpha-2
  • Interferon-alpha
  • Interleukin-2
  • Membrane Glycoproteins
  • Proto-Oncogene Proteins c-bcl-2
  • Protoporphyrins
  • Reactive Oxygen Species
  • Recombinant Proteins
  • bcl-X Protein
  • fas Receptor
  • Superoxides
  • protoporphyrin IX